Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + AG in Metastatic Pancreatic Cancer
NCT04674956Phase 3Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in pancreatic adenocarcinoma (PDAC), sponsored by Renji Hospital. Started Mar 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04674956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674956.